Aeglea BioTherapeutics, Inc.
NASDAQ:AGLE
12.01 (USD) • At close November 27, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 2.329 | 18.739 | 0 | 0 | 3.888 | 5.205 | 4.628 | 6.085 | 0 |
| Cost of Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | 2.329 | 18.739 | 0 | 0 | 3.888 | 5.205 | 4.628 | 6.085 | 0 |
| Gross Profit Ratio
| 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 |
| Reseach & Development Expenses
| 162.79 | 58.579 | 57.069 | 59.638 | 64.6 | 36.719 | 22.815 | 18.143 | 11.453 | 6.83 |
| General & Administrative Expenses
| 45.776 | 28.531 | 27.319 | 21.843 | 15.734 | 12.632 | 10.066 | 8.391 | 5.947 | 2.074 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 45.776 | 28.531 | 27.319 | 21.843 | 15.734 | 12.632 | 10.066 | 8.391 | 5.947 | 2.074 |
| Other Expenses
| 0 | -0.007 | -0.122 | -0.005 | -0.063 | -0.057 | -0.042 | -0.036 | -0.002 | 0 |
| Operating Expenses
| 208.566 | 87.11 | 84.388 | 81.481 | 80.334 | 49.351 | 32.881 | 26.534 | 17.4 | 8.904 |
| Operating Income
| -208.566 | -84.781 | -65.649 | -81.481 | -80.334 | -45.463 | -27.676 | -21.906 | -11.315 | -8.904 |
| Operating Income Ratio
| 0 | -36.402 | -3.503 | 0 | 0 | -11.693 | -5.317 | -4.733 | -1.859 | 0 |
| Total Other Income Expenses Net
| 0.599 | 0.83 | -0.011 | 0.588 | 2.08 | -0.057 | -0.042 | -0.036 | 0.02 | -1.443 |
| Income Before Tax
| -207.967 | -83.951 | -65.66 | -80.893 | -78.254 | -44.348 | -27.236 | -21.698 | -11.295 | -10.347 |
| Income Before Tax Ratio
| 0 | -36.046 | -3.504 | 0 | 0 | -11.406 | -5.233 | -4.688 | -1.856 | 0 |
| Income Tax Expense
| -0.051 | -0.136 | 0.141 | -0.593 | -2.561 | -0.057 | -0.731 | -0.244 | -0.022 | 1.443 |
| Net Income
| -208.018 | -83.815 | -65.801 | -80.3 | -75.693 | -44.348 | -27.236 | -21.698 | -11.295 | -10.347 |
| Net Income Ratio
| 0 | -35.988 | -3.511 | 0 | 0 | -11.406 | -5.233 | -4.688 | -1.856 | 0 |
| EPS
| -0.56 | -24.86 | -25.02 | -37.61 | -59.23 | -53.25 | -45.01 | -55.4 | -24.71 | -37.93 |
| EPS Diluted
| -0.56 | -24.86 | -25.02 | -37.61 | -59.23 | -53.25 | -45.01 | -55.4 | -24.71 | -37.93 |
| EBITDA
| -208.566 | -84.781 | -65.649 | -80.485 | -80.334 | -44.055 | -27.676 | -21.774 | -11.226 | -7.441 |
| EBITDA Ratio
| 0 | -36.402 | -3.503 | 0 | 0 | -11.331 | -5.317 | -4.705 | -1.845 | 0 |